Cargando…
Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate
Mast cell tumours (MCTs) are common canine skin neoplasia. While they generally occur as single tumours, multiple synchronous MCTs (msMCTs) of de novo/non-metastatic origin are reported in a proportion of the patient population. Where there is no evidence of metastasis or lymphatic spread, MCTs are...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643212/ https://www.ncbi.nlm.nih.gov/pubmed/36387404 http://dx.doi.org/10.3389/fvets.2022.1003165 |
_version_ | 1784826471099924480 |
---|---|
author | Brown, Graham K. Finlay, Jessica R. Straw, Rodney C. Ziea, Joy Y. Leung, Becky O'Connell, Kathleen Thomson, Maurine J. Campbell, Justine E. Jones, Pamela D. Reddell, Paul |
author_facet | Brown, Graham K. Finlay, Jessica R. Straw, Rodney C. Ziea, Joy Y. Leung, Becky O'Connell, Kathleen Thomson, Maurine J. Campbell, Justine E. Jones, Pamela D. Reddell, Paul |
author_sort | Brown, Graham K. |
collection | PubMed |
description | Mast cell tumours (MCTs) are common canine skin neoplasia. While they generally occur as single tumours, multiple synchronous MCTs (msMCTs) of de novo/non-metastatic origin are reported in a proportion of the patient population. Where there is no evidence of metastasis or lymphatic spread, MCTs are effectively controlled by surgery and other local therapies. However, treatment of de novo msMCTs can be more challenging, especially when they occur in surgically difficult locations. Here, we report the use of tigilanol tiglate, a novel small molecule registered as a veterinary pharmaceutical for the local treatment of non-metastatic MCTs, in the treatment of patients with msMCTs presenting at three Australian specialist referral centres. We also present a meta-analysis of the literature to provide a better understanding of the prevalence of canine msMCTs. Notably, nine patients with a total of 32 MCTs were treated during the study. A complete response was recorded in 26 (81%) of the individual MCTs on Day 28 after a single tigilanol tiglate injection. Of the 6 initially non-responsive MCTs, one achieved a complete response after a further tigilanol tiglate treatment. A complete response was reported at 6 months in all 22 of the tumours that were evaluable and that had recorded a complete response at Day 84. For the literature meta-analysis, 22 studies were found with prevalence estimates of msMCTs ranging from 3 to 40%; when combined, these studies yielded 3,745 patients with a prevalence of 13% (95% CI 10; 16). Overall, the results demonstrate the utility of intratumoural tigilanol tiglate as an option for the treatment of multiple MCTs where multiple surgical resections would have been required. |
format | Online Article Text |
id | pubmed-9643212 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96432122022-11-15 Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate Brown, Graham K. Finlay, Jessica R. Straw, Rodney C. Ziea, Joy Y. Leung, Becky O'Connell, Kathleen Thomson, Maurine J. Campbell, Justine E. Jones, Pamela D. Reddell, Paul Front Vet Sci Veterinary Science Mast cell tumours (MCTs) are common canine skin neoplasia. While they generally occur as single tumours, multiple synchronous MCTs (msMCTs) of de novo/non-metastatic origin are reported in a proportion of the patient population. Where there is no evidence of metastasis or lymphatic spread, MCTs are effectively controlled by surgery and other local therapies. However, treatment of de novo msMCTs can be more challenging, especially when they occur in surgically difficult locations. Here, we report the use of tigilanol tiglate, a novel small molecule registered as a veterinary pharmaceutical for the local treatment of non-metastatic MCTs, in the treatment of patients with msMCTs presenting at three Australian specialist referral centres. We also present a meta-analysis of the literature to provide a better understanding of the prevalence of canine msMCTs. Notably, nine patients with a total of 32 MCTs were treated during the study. A complete response was recorded in 26 (81%) of the individual MCTs on Day 28 after a single tigilanol tiglate injection. Of the 6 initially non-responsive MCTs, one achieved a complete response after a further tigilanol tiglate treatment. A complete response was reported at 6 months in all 22 of the tumours that were evaluable and that had recorded a complete response at Day 84. For the literature meta-analysis, 22 studies were found with prevalence estimates of msMCTs ranging from 3 to 40%; when combined, these studies yielded 3,745 patients with a prevalence of 13% (95% CI 10; 16). Overall, the results demonstrate the utility of intratumoural tigilanol tiglate as an option for the treatment of multiple MCTs where multiple surgical resections would have been required. Frontiers Media S.A. 2022-10-26 /pmc/articles/PMC9643212/ /pubmed/36387404 http://dx.doi.org/10.3389/fvets.2022.1003165 Text en Copyright © 2022 Brown, Finlay, Straw, Ziea, Leung, O'Connell, Thomson, Campbell, Jones and Reddell. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Veterinary Science Brown, Graham K. Finlay, Jessica R. Straw, Rodney C. Ziea, Joy Y. Leung, Becky O'Connell, Kathleen Thomson, Maurine J. Campbell, Justine E. Jones, Pamela D. Reddell, Paul Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate |
title | Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate |
title_full | Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate |
title_fullStr | Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate |
title_full_unstemmed | Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate |
title_short | Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate |
title_sort | treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate |
topic | Veterinary Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643212/ https://www.ncbi.nlm.nih.gov/pubmed/36387404 http://dx.doi.org/10.3389/fvets.2022.1003165 |
work_keys_str_mv | AT browngrahamk treatmentofmultiplesynchronouscaninemastcelltumoursusingintratumouraltigilanoltiglate AT finlayjessicar treatmentofmultiplesynchronouscaninemastcelltumoursusingintratumouraltigilanoltiglate AT strawrodneyc treatmentofmultiplesynchronouscaninemastcelltumoursusingintratumouraltigilanoltiglate AT zieajoyy treatmentofmultiplesynchronouscaninemastcelltumoursusingintratumouraltigilanoltiglate AT leungbecky treatmentofmultiplesynchronouscaninemastcelltumoursusingintratumouraltigilanoltiglate AT oconnellkathleen treatmentofmultiplesynchronouscaninemastcelltumoursusingintratumouraltigilanoltiglate AT thomsonmaurinej treatmentofmultiplesynchronouscaninemastcelltumoursusingintratumouraltigilanoltiglate AT campbelljustinee treatmentofmultiplesynchronouscaninemastcelltumoursusingintratumouraltigilanoltiglate AT jonespamelad treatmentofmultiplesynchronouscaninemastcelltumoursusingintratumouraltigilanoltiglate AT reddellpaul treatmentofmultiplesynchronouscaninemastcelltumoursusingintratumouraltigilanoltiglate |